Catalyst Pharma’s Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating

Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating on May 12.

Samantha Semenkow’s rating is based on Catalyst Pharma’s strong commercial performance and promising revenue guidance. The company reported robust revenue figures for the first quarter of 2025 across its product lineup, and it has reaffirmed its total product revenue guidance for the year. Notably, the guidance for their key product, Firdapse, appears achievable due to consistent patient acquisition efforts.
Additionally, Catalyst Pharma’s other products, such as Agamree and Fycompa, show potential for meeting or exceeding revenue expectations, despite some uncertainties like the impact of generic competition. The potential effects of the Most-Favored-Nation Executive Order on Catalyst’s portfolio are considered limited, further supporting the positive outlook. Overall, the company’s growing commercial business is viewed as largely de-risked, justifying the Buy rating with a target price of $31 per share.

According to TipRanks, Semenkow is an analyst with an average return of -22.3% and a 25.27% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Larimar Therapeutics, and Argenx Se.

In another report released on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.